Perioperative Bridging With Glycoprotein IIb/IIIa Inhibitors Versus Cangrelor: Balancing Efficacy and Safety.

Joseph S Van TuylAndrea Sikora NewsomeIan B Hollis

Published in: The Annals of pharmacotherapy (2019)

Eptifibatide, tirofiban, and cangrelor are preferred over abciximab as a perioperative bridge. The choice of agent should be tailored to clinical characteristics of the patient and institutional acquisition costs.

Keyphrases

cardiac surgery
patients undergoing
case report
acute kidney injury
smoking cessation
decision making